Daily temozolomide for elderly patients with newly diagnosed brain cancer
Part of Cancer clinical trials.
This trial tests a daily chemo drug (temozolomide) in patients aged 65 or older with a specific type of aggressive brain cancer that has a certain genetic marker. It aims to see if this daily schedule works well after initial radiation and chemo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 65 years or older.
- You have been diagnosed with a new, aggressive brain cancer known as glioblastoma with a specific genetic feature (unmethylated MGMT).
- You have completed a three-week course of radiation with chemo within the last six weeks.
- You are able to care for yourself and perform daily activities (ECOG score 0-2).
- Your blood cell counts and kidney/liver function are within certain limits.
- You do not have other active cancers or serious medical conditions that would interfere.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
This study compares a standard radiation schedule versus a shorter, higher-dose radiation schedule, both with the chemotherapy medicine temozolomide, in older adults with newly diagnosed glioblastoma. It aims to see which approach works better and is practical for people age 70 and older.
This trial tests giving a chemotherapy drug called temozolomide before radiation therapy to people with a newly diagnosed high-grade brain tumor. The goal is to see if this approach can help control the tumor better.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
This trial tests a combination of two drugs (temozolomide and dexbrompheniramine) to treat high-grade gliomas that have come back after standard treatment. The goal is to see if this combination can help control the tumor or slow its growth.
This trial tests a new combination of two drugs (flazoparib and temozolomide) given after the standard initial treatment for glioblastoma. The goal is to see if this combination is safe and effective in preventing the cancer from growing back.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.